Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $500 million aggregate principal amount of its 1.50% exchangeable senior notes due 2024.

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

The Davis Polk corporate team included partner Alan F. Denenberg and counsel Jeffrey Gould. Partner Po Sit and associate Catherine L. Chu provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post